GoodRx (NASDAQ:GDRX) Major Shareholder Equity Vii L.P. Spectrum Sells 16,016 Shares

Key Points

• Equity Vii L.P. Spectrum, a major shareholder of GoodRx Holdings, Inc., sold 16,016 shares at an average price of $4.05, totaling approximately $64,865.
• GoodRx recently reported quarterly earnings of $0.09 per share, missing analysts' expectations of $0.10, and had a revenue of $203.07 million, below the consensus estimate.
• Analysts maintain a mixed outlook on GoodRx, with an average rating of "Hold" and average price target of $5.80 for the stock.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) major shareholder Equity Vii L.P. Spectrum sold 16,016 shares of the stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $4.05, for a total transaction of $64,864.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.

Equity Vii L.P. Spectrum also recently made the following trade(s):

• On Thursday, July 3rd, Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock. The shares were sold at an average price of $4.80, for a total transaction of $51,249.60.

GoodRx Trading Up 3.0%

NASDAQ GDRX traded up $0.12 during trading hours on Monday, reaching $4.12. The company's stock had a trading volume of 3,456,462 shares, compared to its average volume of 2,020,579. The firm has a fifty day simple moving average of $4.51 and a 200-day simple moving average of $4.45. The stock has a market cap of $1.43 billion, a P/E ratio of 41.20, a P/E/G ratio of 1.74 and a beta of 1.23. GoodRx Holdings, Inc. has a 52 week low of $3.31 and a 52 week high of $7.90. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.21 and a quick ratio of 4.21.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). The business had revenue of $203.07 million during the quarter, compared to the consensus estimate of $205.72 million. GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The firm's quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.08 EPS. Equities analysts forecast that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a $6.00 price objective on shares of GoodRx in a report on Monday, August 11th. UBS Group dropped their price objective on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a report on Tuesday, May 13th. Finally, Raymond James Financial lowered shares of GoodRx from a "strong-buy" rating to an "outperform" rating in a report on Friday, August 8th. Five analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $5.80.

Institutional Trading of GoodRx

Hedge funds have recently modified their holdings of the stock. Algert Global LLC bought a new stake in shares of GoodRx in the 1st quarter valued at $1,224,000. Northwestern Mutual Wealth Management Co. increased its stake in shares of GoodRx by 20,956.5% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 14,529 shares of the company's stock valued at $64,000 after acquiring an additional 14,460 shares in the last quarter. Northern Trust Corp increased its stake in shares of GoodRx by 13.5% in the 4th quarter. Northern Trust Corp now owns 421,810 shares of the company's stock valued at $1,961,000 after acquiring an additional 50,256 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of GoodRx in the 1st quarter valued at $315,000. Finally, Raymond James Financial Inc. increased its stake in shares of GoodRx by 54.6% in the 1st quarter. Raymond James Financial Inc. now owns 830,950 shares of the company's stock valued at $3,664,000 after acquiring an additional 293,420 shares in the last quarter. Institutional investors own 63.77% of the company's stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.